164 related articles for article (PubMed ID: 11106111)
21. Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors.
Talbot SM; Westerman DA; Grigg AP; Toner GC; Wolf M; Bishop J; McKendrick J; Zalcberg J; Levi J; Fox RM; Green MD
Ann Oncol; 1999 Aug; 10(8):907-14. PubMed ID: 10509151
[TBL] [Abstract][Full Text] [Related]
22. Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma.
Langeberg WJ; Siozon CC; Page JH; Morrow PK; Chia VM
Support Care Cancer; 2014 Aug; 22(8):2167-75. PubMed ID: 24652049
[TBL] [Abstract][Full Text] [Related]
23. Full-dose CHOP chemotherapy combined with granulocyte colony-stimulating factor for aggressive non-Hodgkin's lymphoma in elderly patients: a prospective study.
Niitsu N; Iijima K
Ann Hematol; 2001 Oct; 80(10):602-6. PubMed ID: 11732872
[TBL] [Abstract][Full Text] [Related]
24. Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).
Verdonck LF; Notenboom A; de Jong DD; MacKenzie MA; Verhoef GE; Kramer MH; Ossenkoppele GJ; Doorduijn JK; Sonneveld P; van Imhoff GW
Blood; 2007 Apr; 109(7):2759-66. PubMed ID: 17132720
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes?
Gregory SA; Trümper L
Ann Oncol; 2005 Sep; 16(9):1413-24. PubMed ID: 15932900
[TBL] [Abstract][Full Text] [Related]
26. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma.
Doorduijn JK; Buijt I; van der Holt B; van Agthoven M; Sonneveld P; Uyl-de Groot CA
Haematologica; 2004 Sep; 89(9):1109-17. PubMed ID: 15377472
[TBL] [Abstract][Full Text] [Related]
27. Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphoma.
Dranitsaris G; Altmayer C; Quirt I
Pharmacoeconomics; 1997 Jun; 11(6):566-77. PubMed ID: 10173030
[TBL] [Abstract][Full Text] [Related]
28. CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma: a pilot study. The Adult Lymphoma Treatment Study Group (ALTSG).
Niitsu N; Okamoto M; Kuraishi Y; Nakamura S; Kodama F; Hirano M
Eur J Haematol; 2000 Sep; 65(3):188-94. PubMed ID: 11007055
[TBL] [Abstract][Full Text] [Related]
29. Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support.
Cabanillas F; Cotto M; Liboy I; Rivera E; Pavia OA; Bruno M
Leuk Lymphoma; 2012 Oct; 53(10):1929-33. PubMed ID: 22448918
[TBL] [Abstract][Full Text] [Related]
30. High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.
Peterson BA; Johnson J; Shipp MA; Barcos M; Gockerman JP; Canellos GP;
Leuk Lymphoma; 2007 May; 48(5):870-80. PubMed ID: 17487729
[TBL] [Abstract][Full Text] [Related]
31. A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma.
Burton C; Linch D; Hoskin P; Milligan D; Dyer MJ; Hancock B; Mouncey P; Smith P; Qian W; MacLennan K; Jack A; Webb A; Cunningham D
Br J Cancer; 2006 Mar; 94(6):806-13. PubMed ID: 16508640
[TBL] [Abstract][Full Text] [Related]
32. Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma.
Niitsu N; Umeda M
Eur J Haematol; 1996 Mar; 56(3):163-7. PubMed ID: 8598236
[TBL] [Abstract][Full Text] [Related]
33. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
34. Delivery of full dose CHOP chemotherapy to elderly patients with aggressive non-Hodgkin's lymphoma without G-CSF support.
Campbell C; Sawka C; Franssen E; Berinstein NL
Leuk Lymphoma; 1999 Sep; 35(1-2):119-27. PubMed ID: 10512169
[TBL] [Abstract][Full Text] [Related]
35. Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma.
Yokose N; Ogata K; Tamura H; An E; Nakamura K; Kamikubo K; Kudoh S; Dan K; Nomura T
Br J Cancer; 1998 Jun; 77(12):2286-90. PubMed ID: 9649147
[TBL] [Abstract][Full Text] [Related]
36. Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas.
Silvestri F; Velisig M; Fanin R; Virgolini L; Zaja F; Barillari G; Baccarani M
Leuk Lymphoma; 1995 Feb; 16(5-6):465-70. PubMed ID: 7540461
[TBL] [Abstract][Full Text] [Related]
37. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
[TBL] [Abstract][Full Text] [Related]
38. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma.
Tulpule A; Espina BM; Berman N; Buchanan LH; Smith DL; Sherrod A; Dharmapala D; Gee C; Boswell WD; Nathwani BN; Welles L; Levine AM
Clin Lymphoma Myeloma; 2006 Jul; 7(1):59-64. PubMed ID: 16879771
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B.
Lichtman SM; Niedzwiecki D; Barcos M; Carlisle TL; Cooper MR; Johnson JL; Peterson BA
Ann Oncol; 2000 Sep; 11(9):1141-6. PubMed ID: 11061609
[TBL] [Abstract][Full Text] [Related]
40. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.
Mori M; Kitamura K; Masuda M; Hotta T; Miyazaki T; Miura AB; Mizoguchi H; Shibata A; Saito H; Matsuda T; Masaoka T; Harada M; Niho Y; Takaku F
Int J Hematol; 2005 Apr; 81(3):246-54. PubMed ID: 15814336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]